Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.

Also called NCT06682351

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06682351
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06682351. Randomized; no masking; primary purpose treatment. Start 2024-11 (anticipated); primary completion 2027-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention
Condition
Prediabetes / Type 2 Diabetes
Intervention (Drug)
Metformin
Intervention (Drug)
GLP-1A
Intervention (Dietary supplement)
MED
Lead sponsor
Stanford University (class: other)

Record details

Record id
cardio:ct-nct06682351
Content hash
7b38901d37ec90e3c9bb00d7a0b6ce68fcdbfc5568960ed448a6d47378db92c1